Why the study?
The study sought to compare the comparative safety and effectiveness of DOACs in patients with non-valvular atrial fibrillation initiating dabigatran versus rivaroxaban or apixaban.
Does dabigatran reduce major bleeding or stroke compared to rivaroxaban or apixaban in adults with non-valvular atrial fibrillation?
Population
Adults with NVAF newly initiated on standard-dose DOAC from the US Department of Defense database
Comparison
Dabigatran vs rivaroxaban and dabigatran vs apixaban
Design
Retrospective propensity score-matched cohort study
Authors
Loading...
Should not yet change NOAC selection in NVAF; extends observational comparisons but leaves randomized confirmation open.
Does dabigatran reduce major bleeding or stroke compared to rivaroxaban or apixaban in adults with non-valvular atrial fibrillation?
In real-world patients with NVAF, standard-dose dabigatran is associated with a lower risk of major bleeding compared to rivaroxaban, with similar effectiveness for stroke prevention.
Villines et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: